Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Artificial intelligence models are forecasting a notable rise in Eli Lilly's stock prices. These AI-driven algorithms analyze ...

Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. These ...

Looking for the latest stock opportunities in March 2025? We have you covered. Click to read our top stock picks to consider ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...

The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic ...

Many employers and insurers are scaling back coverage of Wegovy and Zepbound, and a key government program, Medicare, doesn’t ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...